 |
|
| Venture Capital Bio Life Sciences (page 14 of 20) |
|
-Pacific-
Offices: Encino-Irvine, California
Pacific Venture Group serves as the lead investor in early and expansion-stage
companies with high growth and profit potential across all segments of healthcare.
Their venture capital professionals are committed to using their experience
and contacts in concert with Management to build successful companies which
are leaders in their industry. The firm currently manages two venture funds
whose limited partners include pension funds, financial institutions, and
healthcare companies.
Offices: Durham-Research Triangle, North Carolina
At Pappas Ventures, their sole focus is investing in the life sciences—biotechnology,
specialty pharmaceuticals, drug delivery, medical devices and related ventures.
their success, however, is not simply a product of investment capital. They
bring experience, creativity and passion to each and every partnership.
And in so doing, they’re bringing promising technologies to commercial application—from
concept to commerce.
Offices: Indianapolis, Indiana; Gaithersburg, Maryland & Los Angeles,
California
Pearl Street Venture Funds’ strategy is to invest in therapeutic product
companies that develop and integrate the “next generation” of technologies.
These companies would ideally fill the pipelines of large pharmaceutical
companies with drugs that have the potential to treat the underlying causes
of important human diseases.
Offices: Pittsburgh, Pennsylvania
The Pittsburgh Life Sciences Greenhouse was created specifically to build
on Pittsburgh's strengths in the Life Sciences enabling the region to become
a premier national and international center in their targeted areas. By
helping researchers and entrepreneurs get their ideas and discoveries into
the marketplace, PLSG will help build the critical mass of Life Sciences
organizations necessary to improve the regional economy and quality of life.
Offices: Carlsbad, California
POSCO BioVentures is a venture capital fund dedicated solely to biotechnology
investments. POSCO BioVentures has only one limited partner, POSCO, the
$20 billion Korean steel company through its American subsidiary POSAM.
POSCO has made a strategic decision to diversify, and the first step in
its diversification strategy is focused on building a biotechnology business.
Investments are made across all stages of early company development and
in a variety of disciplines, including therapeutics, diagnostics, platform
technologies, and non-life science companies. -Prolog-
Offices: St Louis, Missouri
Prolog is a venture capital firm with approximately $100 million under management
specializing in life sciences and related information technologies. Prolog
invests in companies that pursue solutions in life sciences, health care,
and related information technologies. They are proud of their portfolio
companies, and they are committed to helping them achieve wise growth and
long-term success. Prolog's value is enhanced by their team members' long-standing
connections with many other venture capital firms, to whom they can turn
for syndication of larger investment rounds.
Offices: Princeton, New Jersey & San Diego, California
ProQuest is a healthcare venture capital firm with over $350 million under
management. They invest in healthcare companies seeking seed to late-stage
financing. Their portfolio reflects the rich diversity of the healthcare
industry and exemplifies their commitment to fostering the growth of exceptional
businesses. In addition to their breadth of experience across many sectors
of the healthcare industry, they have special expertise in therapeutics,
where innovations in drug discovery technologies and molecular analysis
are transforming an enormous unmet medical need and offering great commercial
opportunities to build value.
Offices: Palo Alto, California
Prospect Venture Partners has $600M of capital under management. The firm
is dedicated to investing in outstanding biomedical technology and life
science companies. Prospect targets commercially attractive health care
enterprises with outstanding entrepreneurial management teams, proprietary
products, and innovative technology or services with potential for significant
investment returns. The firm invests in companies with a broad range of
development and financing requirements including: (a) incubating new companies,
(b) investing in first and second venture financing rounds, and (c) participating
in later stage private and public companies with proven business models
requiring expansion capital.
Offices: New York, New York
Founded in 1998, Psilos Group is a venture capital firm specializing in
investments in companies in the healthcare sector. With over $230 million
under management, the firm applies the significant entrepreneurial, operating
and investment experience of their principals and advisory board members
to help their portfolio companies establish themselves in the market and
build their long-term growth potential. The company is currently investing
from its Psilos II fund, with a focus on revenue stage and later stage companies.
Offices: Houston, Texas
PTV Sciences was founded in 2003 to invest in seed and early stage growth
opportunities in life and material sciences. Much like the untapped reserves
which created the modern day oil and gas industry in 1901, the Texas region
and the Southern US has a wealth of untapped resources in its academic institutions
and research centers. The Firm has the benefit of the direct experience
and infrastructure support of the principals, who over the last century
have been investing in and building sustainable, successful companies in
energy, financial services, agriculture and real estate.
Offices: Boston, Massachusetts
Puretech specializes in seed and early-stage investment in novel therapeutics,
medical devices, and research technologies. They focus on major unmet medical
needs that have yet to be addressed by emerging science. Enlisting the world’s
leading academic and industry experts, they identify novel technologies
(often prior to publication) and create companies that drive those discoveries
to commercially and clinically driven milestones.
Print
(page 15)
Resources
to
top